Literature DB >> 32956141

How Are Indeterminate Pulmonary Nodules at Diagnosis Associated with Survival in Patients with High-Grade Osteosarcoma?

Kim M Tsoi1,2, Martin Lowe1, Yusuke Tsuda1, Johnathan R Lex1, Tomohiro Fujiwara1, Ghassan Almeer3, Jonathan Gregory1, Jonathan Stevenson1,4, Scott E Evans1, Rajesh Botchu3, Lee M Jeys1,4.   

Abstract

BACKGROUND: Pulmonary metastases are a poor prognostic factor in patients with osteosarcoma; however, the clinical significance of subcentimeter lung nodules and whether they represent a tumor is not fully known. Because the clinician is faced with decisions regarding biopsy, resection, or observation of lung nodules and the potential impact they have on decisions about resection of the primary tumor, this remains an area of uncertainty in patient treatment. Surgical management of the primary tumor is tailored to prognosis, and it is unclear how aggressively patients with indeterminate pulmonary nodules (IPNs), defined as nodules smaller than 1 cm at presentation, should be treated. There is a clear need to better understand the clinical importance of these nodules. QUESTIONS/PURPOSES: (1) What percentage of patients with high-grade osteosarcoma and spindle cell sarcoma of bone have IPNs at diagnosis? (2) Are IPNs at diagnosis associated with worse metastasis-free and overall survival? (3) Are there any clinical or radiologic factors associated with worse overall survival in patients with IPN?
METHODS: Between 2008 and 2016, 484 patients with a first presentation of osteosarcoma or spindle cell sarcoma of bone were retrospectively identified from an institutional database. Patients with the following were excluded: treatment at another institution (6%, 27 of 484), death related to complications of neoadjuvant chemotherapy (1%, 3 of 484), Grade 1 or 2 on final pathology (4%, 21 of 484) and lack of staging chest CT available for review (0.4%, 2 of 484). All patients with abnormalities on their staging chest CT underwent imaging re-review by a senior radiology consultant and were divided into three groups for comparison: no metastases (70%, 302 of 431), IPN (16%, 68 of 431), and metastases (14%, 61 of 431) at the time of diagnosis. A random subset of CT scans was reviewed by a senior radiology registrar and there was very good agreement between the two reviewers (κ = 0.88). Demographic and oncologic variables as well as treatment details and clinical course were gleaned from a longitudinally maintained institutional database. The three groups did not differ with regard to age, gender, subtype, presence of pathological fracture, tumor site, or chemotherapy-induced necrosis. They differed according to local control strategy and tumor size, with a larger proportion of patients in the metastases group presenting with larger tumor size and undergoing nonoperative treatment. There was no differential loss to follow-up among the three groups. Two percent (6 of 302) of patients with no metastases, no patients with IPN, and 2% (1 of 61) of patients with metastases were lost to follow-up at 1 year postdiagnosis but were not known to have died. Individual treatment decisions were determined as part of a multidisciplinary conference, but in general, patients without obvious metastases received (neo)adjuvant chemotherapy and surgical resection for local control. Patients in the no metastases and IPN groups did not differ in local control strategy. For patients in the IPN group, staging CT images were inspected for IPN characteristics including number, distribution, size, location, presence of mineralization, and shape. Subsequent chest CT images were examined by the same radiologist to reevaluate known nodules for interval change in size and to identify the presence of new nodules. A random subset of chest CT scans were re-reviewed by a senior radiology resident (κ = 0.62). The association of demographic and oncologic variables with metastasis-free and overall survival was first explored using the Kaplan-Meier method (log-rank test) in univariable analyses. All variables that were statistically significant (p < 0.05) in univariable analyses were entered into Cox regression multivariable analyses.
RESULTS: Following re-review of staging chest CTs, IPNs were found in 16% (68 of 431) of patients, while an additional 14% (61 of 431) of patients had lung metastases (parenchymal nodules 10 mm or larger). After controlling for potential confounding variables like local control strategy, tumor size, and chemotherapy-induced necrosis, we found that the presence of an IPN was associated with worse overall survival and a higher incidence of metastases (hazard ratio 1.9 [95% CI 1.3 to 2.8]; p = 0.001 and HR 3.6 [95% CI 2.5 to 5.2]; p < 0.001, respectively). Two-year overall survival for patients with no metastases, IPN, or metastases was 83% [95% CI 78 to 87], 65% [95% CI 52 to 75] and 45% [95% CI 32 to 57], respectively (p = 0.001). In 74% (50 of 68) of patients with IPNs, it became apparent that they were true metastatic lesions at a median of 5.3 months. Eighty-six percent (43 of 50) of these patients had disease progression by 2 years after diagnosis. In multivariable analysis, local control strategy and tumor subtype correlated with overall survival for patients with IPNs. Patients who were treated nonoperatively and who had a secondary sarcoma had worse outcomes (HR 3.6 [95% CI 1.5 to 8.3]; p = 0.003 and HR 3.4 [95% CI 1.1 to 10.0]; p = 0.03). The presence of nodule mineralization was associated with improved overall survival in the univariable analysis (87% [95% CI 39 to 98] versus 57% [95% CI 43 to 69]; p = 0.008), however, because we could not control for other factors in a multivariable analysis, the relationship between mineralization and survival could not be determined. We were unable to detect an association between any other nodule radiologic features and survival.
CONCLUSION: The findings show that the presence of IPNs at diagnosis is associated with poorer survival of affected patients compared with those with normal staging chest CTs. IPNs noted at presentation in patients with high-grade osteosarcoma and spindle cell sarcoma of bone should be discussed with the patient and be considered when making treatment decisions. Further work is required to elucidate how the nodules should be managed. LEVEL OF EVIDENCE: Level III, prognostic study.
Copyright © 2020 by the Association of Bone and Joint Surgeons.

Entities:  

Mesh:

Year:  2021        PMID: 32956141      PMCID: PMC7899536          DOI: 10.1097/CORR.0000000000001491

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.755


  26 in total

1.  Computed tomographic criteria for the discrimination of subcentimeter lung nodules in patients with soft-tissue sarcomas.

Authors:  Oliver Dudeck; M Zeile; D Andreou; D Schnapauff; M Pech; G Wieners; J Ricke; P Reichardt; P-U Tunn
Journal:  Clin Imaging       Date:  2011 May-Jun       Impact factor: 1.605

2.  CT characteristics of lung nodules present at diagnosis of extrapulmonary malignancy in children.

Authors:  Cicero Torres Silva; Joao Guilherme Amaral; Rahim Moineddin; Wendy Doda; Paul S Babyn
Journal:  AJR Am J Roentgenol       Date:  2010-03       Impact factor: 3.959

3.  Pulmonary perifissural nodules on CT scans: rapid growth is not a predictor of malignancy.

Authors:  Bartjan de Hoop; Bram van Ginneken; Hester Gietema; Mathias Prokop
Journal:  Radiology       Date:  2012-08-28       Impact factor: 11.105

4.  Computed tomography of pulmonary metastases from osteosarcoma: the less poor technique. A study of 51 patients with histological correlation.

Authors:  P Picci; D Vanel; A Briccoli; K Talle; U Haakenaasen; C Malaguti; C Monti; C Ferrari; G Bacci; G Saeter; T A Alvegard
Journal:  Ann Oncol       Date:  2001-11       Impact factor: 32.976

5.  The many faces of pulmonary metastases of osteosarcoma: Retrospective study on 283 lesions submitted to surgery.

Authors:  Federica Ciccarese; Alberto Bazzocchi; Rosanna Ciminari; Alberto Righi; Michele Rocca; Eugenio Rimondi; Piero Picci; Maria L Bacchi Reggiani; Ugo Albisinni; Maurizio Zompatori; Daniel Vanel
Journal:  Eur J Radiol       Date:  2015-10-01       Impact factor: 3.528

6.  Pulmonary Nodule Size <5 mm Still Warrants Investigation in Patients With Osteosarcoma and Ewing Sarcoma.

Authors:  Jared Kusma; Cody Young; Han Yin; Joseph R Stanek; Nicholas Yeager; Jennifer H Aldrink
Journal:  J Pediatr Hematol Oncol       Date:  2017-04       Impact factor: 1.289

7.  Probability of cancer in pulmonary nodules detected on first screening CT.

Authors:  Annette McWilliams; Martin C Tammemagi; John R Mayo; Heidi Roberts; Geoffrey Liu; Kam Soghrati; Kazuhiro Yasufuku; Simon Martel; Francis Laberge; Michel Gingras; Sukhinder Atkar-Khattra; Christine D Berg; Ken Evans; Richard Finley; John Yee; John English; Paola Nasute; John Goffin; Serge Puksa; Lori Stewart; Scott Tsai; Michael R Johnston; Daria Manos; Garth Nicholas; Glenwood D Goss; Jean M Seely; Kayvan Amjadi; Alain Tremblay; Paul Burrowes; Paul MacEachern; Rick Bhatia; Ming-Sound Tsao; Stephen Lam
Journal:  N Engl J Med       Date:  2013-09-05       Impact factor: 91.245

8.  Survival of pediatric patients after relapsed osteosarcoma: the St. Jude Children's Research Hospital experience.

Authors:  Sarah E S Leary; Amy W Wozniak; Catherine A Billups; Jianrong Wu; Valerie McPherson; Michael D Neel; Bhaskar N Rao; Najat C Daw
Journal:  Cancer       Date:  2013-04-26       Impact factor: 6.860

9.  Outcome for adolescent and young adult patients with osteosarcoma: a report from the Children's Oncology Group.

Authors:  Katherine A Janeway; Donald A Barkauskas; Mark D Krailo; Paul A Meyers; Cindy L Schwartz; David H Ebb; Nita L Seibel; Holcombe E Grier; Richard Gorlick; Neyssa Marina
Journal:  Cancer       Date:  2012-01-17       Impact factor: 6.860

10.  Development and external validation of nomograms predicting distant metastases and overall survival after neoadjuvant chemotherapy and surgery for patients with nonmetastatic osteosarcoma: A multi-institutional study.

Authors:  Koichi Ogura; Tomohiro Fujiwara; Hideo Yasunaga; Hiroki Matsui; Dae-Geun Jeon; Wan Hyeong Cho; Hiroaki Hiraga; Takeshi Ishii; Tsukasa Yonemoto; Hiroto Kamoda; Toshifumi Ozaki; Eiji Kozawa; Yoshihiro Nishida; Hideo Morioka; Toru Hiruma; Shigeki Kakunaga; Takafumi Ueda; Yusuke Tsuda; Hirotaka Kawano; Akira Kawai
Journal:  Cancer       Date:  2015-07-20       Impact factor: 6.860

View more
  5 in total

1.  How to confront the high prevalence of pulmonary micro nodules (PMNs) in osteosarcoma patients?

Authors:  Zhenyu Cai; Jie Xu; Xin Sun; Ranxin Zhang; Lu Xie; Jichuan Wang; Xiaodong Tang; Rongli Yang; Wei Guo
Journal:  Int Orthop       Date:  2022-08-09       Impact factor: 3.479

2.  Indeterminate pulmonary nodules are not associated with worse overall survival in Ewing Sarcoma.

Authors:  K M Tsoi; D Tan; J Stevenson; S Evans; L M Jeys; R Botchu
Journal:  J Clin Orthop Trauma       Date:  2021-01-23

3.  CORR Insights®: How Are Indeterminate Pulmonary Nodules at Diagnosis Associated with Survival in Patients with High-Grade Osteosarcoma?

Authors:  Lauren W Averill
Journal:  Clin Orthop Relat Res       Date:  2021-02-01       Impact factor: 4.755

4.  Osteosarcoma immune prognostic index can indicate the nature of indeterminate pulmonary nodules and predict the metachronous metastasis in osteosarcoma patients.

Authors:  Xuanhong He; Minxun Lu; Xin Hu; Longqing Li; Chang Zou; Yi Luo; Yong Zhou; Li Min; Chongqi Tu
Journal:  Front Oncol       Date:  2022-07-22       Impact factor: 5.738

5.  Lung Immune Prognostic Index Could Predict Metastasis in Patients With Osteosarcoma.

Authors:  Xuanhong He; Yitian Wang; Qiang Ye; Yang Wang; Li Min; Yi Luo; Yong Zhou; Chongqi Tu
Journal:  Front Surg       Date:  2022-07-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.